Sleep, Growth, and Puberty After Two Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder
A recent 3-month double-blind placebo-controlled study demonstrated efficacy and safety of child-appropriate prolonged-release melatonin (PedPRM) for insomnia in children with autism spectrum disorder (ASD). Here, we report on the long-term effects of PedPRM treatment on sleep, growth, body mass index, and pubertal development.
Conditions: Autism Spectrum Disorder; Cognitive Behaviour Therapy Interventions: Behavioral: Cognitive behaviour therapy for insomnia; Behavioral: psychoeducation for ASD Sponsor: Shanghai Jiao Tong University School of Medicine Recruiting
Journal of Clinical Sleep Medicine, Ahead of Print.
This study examined the long-term effects of PedPRM treatment on sleep, growth, body mass index, and pubertal development.
IJERPH, Vol. 17, Pages 400: The Prevalence of Insomnia and the Link between Iron Metabolism Genes Polymorphisms, TF rs1049296 C>T, TF rs3811647 G>A, TFR rs7385804 A>C, HAMP rs10421768 A>G and Sleep Disorders in Polish Individuals with ASD International Journal of Environmental Research and Public Health doi: 10.3390/ijerph17020400 Authors: Karolina Skonieczna-Żydecka Dominika Jamioł-Milc Krzysztof Borecki Ewa Stachowska Paulina Zabielska Magdalena Kamińska Beata Karakiewicz Iron deficiency have been found to be linked to sleep disorders. Both genetic and environmental factors are risk fac...
Insomnia and low iron stores are common in children with autism spectrum disorders (ASD) and low iron stores have been associated with sleep disturbance. A randomized placebo-controlled trial of oral ferrous sulfate to treat insomnia in children with ASD and low normal ferritin levels was performed.
In conclusion, this review highlights the importance for clinicians to investigate for the presence of chronic nightmares along with other sleep difficulties (most commonly, insomnia and sleep apnea), to consider the potential influence of nightmares on the course of the primary mental disorder, and to be prepared to grant access to treatments targeting nightmares. (PsycINFO Database Record (c) 2019 APA, all rights reserved)
CONCLUSIONS: Clinicians and carers should be aware that sleep problems are common in 22q11.2DS and index psychiatric risk, cognitive deficits and motor coordination problems. Future studies should explore the physiology of sleep and the links with the neurodevelopment in these young people. PMID: 31144615 [PubMed - as supplied by publisher]
Abstract A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2-17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2-5 mg) in improving sleep duration and onset. Treatment effects on child behavior and caregiver's quality of life were evaluated. PedPRM treatment resulted in significant improvement in externalizing but not internalizing behavior (Strengths and Difficulties questionnaire; SDQ) compared to placebo (p = 0.021) with cli...